Skip to main content
GALECTIN THERAPEUTICS INC logo

GALECTIN THERAPEUTICS INC — Investor Relations & Filings

Ticker · GALT ISIN · US3632252025 LEI · 5299004HFYSAZM2ALW85 US Manufacturing
Open in API
Filings indexed 1,091 across all filing types
Latest filing 2014-08-15 Director's Dealing
Country US United States of America
Listing US GALT

About GALECTIN THERAPEUTICS INC

https://galectintherapeutics.com/

Galectin Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies for fibrotic diseases, chronic liver disease, and cancer. The company's therapeutic approach centers on inhibiting the galectin-3 protein, which is implicated in various inflammatory, fibrotic, and malignant conditions. Its lead drug candidate, belapectin (GR-MD-02), is a proprietary carbohydrate-based drug designed to bind to and inhibit galectin-3. The primary development program for belapectin is focused on treating non-alcoholic steatohepatitis (MASH) with cirrhosis, a serious liver disease with no currently approved therapies.

Recent filings

Filing Released Lang Actions
PRIMARY DOCUMENT
Director's Dealing
2014-08-15 English
PRIMARY DOCUMENT
Director's Dealing
2014-08-15 English
PRIMARY DOCUMENT
Director's Dealing
2014-08-14 English
S-8
Regulatory Filings Classification · 100% confidence The document is a Form S-8 Registration Statement filed with the U.S. Securities and Exchange Commission. It registers additional shares of common stock under an existing Incentive Compensation Plan. The document includes legal and regulatory disclosures, incorporation by reference of prior filings (10-K, 10-Q, 8-K), and details about indemnification of directors and officers. It is not a financial report, earnings release, or management discussion, but a regulatory filing related to securities registration under the Securities Act of 1933. Therefore, it fits the category of Regulatory Filings (RNS).
2014-08-12 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated August 7, 2014, by Galectin Therapeutics Inc. It specifically references Item 2.02 "Results of Operations and Financial Condition" and states that the company issued a press release announcing its financial results for the quarter ended June 30, 2014. The document includes the press release as an exhibit but does not contain detailed financial statements or substantive financial data itself. The text also clarifies that the information is being furnished, not filed, and is a summary announcement of financial results rather than a full financial report. Given the document length is under 5,000 characters and it primarily announces the earnings results via a press release, this fits the definition of an Earnings Release (ER).
2014-08-07 English
FORM 10-Q
Interim / Quarterly Report Q2 2014
2014-08-07 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.